Macquarie Group LTD Biotechnology

Macquarie Group LTD

$86.4 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
CGEN Compugen LTD	$182M	$1.56 Million 0.0% of portfolio	1,020,000	Q1 2024 Added 2.0%
SMMT Summit Therapeutics Inc.	$4.45B	$1.53 Million 0.0% of portfolio	85,753	Q4 2024 New
DAWN Day One Biopharmaceuticals, Inc.	$913M	$1.39 Million 0.0% of portfolio	110,000	Q3 2024 Reduced 0.55%
MGNX Macrogenics Inc	$170M	$1.37 Million 0.0% of portfolio	420,000	Q4 2022 Reduced 0.12%
CHRS Coherus Bio Sciences, Inc.	$83.2M	$1.24 Million 0.0% of portfolio	899,999	Q1 2024 Added 38.46%
RPRX Royalty Pharma PLC	$14.6B	$1.18 Million 0.0% of portfolio	46,148	Q4 2024 Reduced 1.37%
RGNX Regenxbio Inc.	$314M	$1.15 Million 0.0% of portfolio	149,000	Q4 2022 Reduced 0.22%
VTYX Ventyx Biosciences, Inc.	$91M	$941,000 0.0% of portfolio	430,000	Q1 2024 New
RCKT Rocket Pharmaceuticals, Inc.	$792M	$729,000 0.0% of portfolio	58,000	Q4 2022 Reduced 0.54%
ALT Altimmune, Inc.	$315M	$721,000 0.0% of portfolio	100,000	Q2 2024 Added 124.85%
ARGX Argenx Se	$35.7B	$432,000 0.0% of portfolio	704	Q4 2023 Added 163.67%
CLLS Cellectis S.A.	$69.6M	$408,000 0.0% of portfolio	226,875	Q3 2020 Added 3.28%
SGMO Sangamo Therapeutics, Inc	$168M	$408,000 0.0% of portfolio	400,000	Q3 2024 Reduced 1.88%
KPTI Karyopharm Therapeutics Inc.	$47.9M	$340,000 0.0% of portfolio	500,000	Q3 2024 Reduced 1.12%
ALLO Allogene Therapeutics, Inc.	$312M	$312,000 0.0% of portfolio	146,779	Q4 2022 Reduced 0.4%
NKTR Nektar Therapeutics	$174M	$238,000 0.0% of portfolio	256,385	Q4 2022 Reduced 0.99%
AVIR Atea Pharmaceuticals, Inc.	$257M	$234,000 0.0% of portfolio	70,000	Q4 2022 Reduced 2.1%
NTLA Intellia Therapeutics, Inc.	$925M	$233,000 0.0% of portfolio	20,000	Q4 2022 Reduced 2.34%
LEGN Legend Biotech Corp	$6.65B	$224,000 0.0% of portfolio	6,887	Q4 2023 Added 22.89%
MRSN Mersana Therapeutics, Inc.	$51.5M	$214,000 0.0% of portfolio	150,000	Q4 2022 Reduced 2.47%
PBYI Puma Biotechnology, Inc.	$133M	$186,000 0.0% of portfolio	61,255	Q2 2024 Reduced 2.44%
NXTC Next Cure, Inc.	$20M	$115,000 0.0% of portfolio	150,000	Q1 2022 Reduced 0.16%
AMRN Amarin Corp Plcuk	$238M	$111,000 0.0% of portfolio	232,655	Q4 2024 Added 22.45%
XOMA Xoma Corp	$269M	$91,000 0.0% of portfolio	3,466	Q2 2020 Reduced 36.29%
OCUL Ocular Therapeutix, Inc	$539M	$90,000 0.0% of portfolio	10,548	Q4 2024 New
ALDX Aldeyra Therapeutics, Inc.	$390M	$48,000 0.0% of portfolio	9,791	Q4 2024 New
ATXS Astria Therapeutics, Inc.	$103M	$41,000 0.0% of portfolio	4,658	Q4 2024 New
THRD Third Harmonic Bio, Inc.	$140M	$41,000 0.0% of portfolio	4,040	Q4 2024 New
VYGR Voyager Therapeutics, Inc.	$163M	$32,000 0.0% of portfolio	5,700	Q1 2022 Reduced 7.54%
IGMS Igm Biosciences, Inc.	$40M	$20,000 0.0% of portfolio	3,342	Q4 2024 New
NVO Novo Nordisk A S	$199B	$8,000 0.0% of portfolio	103	Q4 2024 Reduced 1.9%
GMAB Genmab A/S	$14.7B	$6,000 0.0% of portfolio	314	Q4 2024 Added 36.52%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.